Article Information
History
- February 7, 2022.
Article Versions
- Version 1 (December 15, 2021 - 23:14).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Ryan Y.S. Keh1,2,
- Sophie Scanlon3,
- Preeti Datta-Nemdharry3,
- Katherine Donegan3,
- Sally Cavanagh4,
- Mark Foster5,
- David Skelland6,
- James Palmer4,
- Pedro M. Machado1,7,
- Stephen Keddie1,7,8,
- Aisling S. Carr1,7,
- Michael P. Lunn1,7,*,
- BPNS/ABN COVID-19 Vaccine GBS Study Group
- 1MRC Centre for Neuromuscular Diseases, National Hospital of Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Foundation Trust, London, UK
- 2Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester, UK
- 3Medicines and Healthcare products Regulatory Agency, UK
- 4NHS England & Improvement (NHSEI), National Health Service, UK
- 5Medical Data Solutions and Services (MDSAS) Ltd, data platform provider for the National Immunoglobulin Database
- 6NHS Arden and Greater East Midlands (GEM) Commissioning Support Unit (CSU), UK
- 7Institute of Neurology, University College London, London, UK
- 8Department of Neurology, The Royal London Hospital, Barts Health NHS Trust, London, UK
- ↵*Correspondence to: Michael P. Lunn, MRC Centre for Neuromuscular Diseases, National Hospital of Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Foundation Trust, London, UK, michaellunn{at}nhs.net
Posted February 07, 2022.
COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database
